还珠格格

China's pharmaceutical industry sees accelerated innovation breakthroughs in H1_我的网站

A | (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed. China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval. A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country. Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category. This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading. At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly. To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong. The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions. In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total. (By Tang Yuxian) 。日报讯（记者高珊）8月19日是第九个中国医师节，中央宣传部、国家卫生健康委向全社会公开发布“最美医生”先进事迹。全国共有9名优秀医务工作者光荣入选，邢台市清河县中心医院老年病科主任顾翠英名列其中。顾翠英，1972年9月生，从20岁投身医疗卫生事业起，已默默耕耘三十余年。2013年，清河县中心医院成立老年病科。面对人才、设备、场地等方面的不足，她主动请缨，以单位为家，将全部精力扑在工作上。在她的带领下，科室床位从最初的56张扩展到178张，并逐步开展了老年康复、安宁疗护、营养评估与咨询等多项服务，每年服务老年患者3000余人次。近年来，她先后获评“全国五一劳动奖章”“全国敬老爱老助老模范人物”“中国好医生”“好人”等荣誉称号。